Hope to erase the blurry vision of age

Ever held a newspaper at arm’s length to read the fine print?

Then you might benefit from the development of eye drops that literally could change the way some 100 million Americans see.

The drops were developed by Encore Vision with support from the Tech Fort Worth-UNT Health Science Center Accelerator Lab. They treat presbyopia, a condition that causes blurry near vision as people age.

"Right now there is no medical treatment for presbyopia, just glasses or surgery," said Bill Burns, Encore Vision President and CEO. "And presbyopia is a condition that virtually everyone over 45 experiences."

The eye drops work by reducing stiffness in the eye lens that occurs with aging. By restoring flexibility, the drops allow the lens to thicken in the center, making it easier to focus on nearby objects.

"The drops are made from natural agents found in the body," Burns said. "So the body doesn’t have to figure out how to metabolize them, a key safety feature."

Burns turned to the TechFW-UNTHSC Accelerator Lab for help in the early stages of development. Having access to lab space, equipment and other facilities was a real benefit, he said.

"The resources available at the Accelerator Lab have proven to be an enormous asset to a start-up company like ours," he said. "The easy access to the vast treasure trove of publications, data and research was truly essential."

"Encore Vision was the right kind of company for the partnership represented by the TechFW-UNTHSC Accelerator Lab," said Joe Allred, Associate Vice President for Research and Innovation.
The way Encore Vision has progressed is a good example of how TechFW and UNTHSC provide much more than just space for Accelerator Lab clients, said Darlene Boudreaux, Executive Director of Tech Fort Worth.

"TechFW staff helped Bill put together a business model that would work, coached him on presenting a business that would interest the right investors, then put him in front of our Cowtown Angel Network," she said.

Encore Vision expects to move to human clinical trials by early next year. The therapeutic dosage has not been established, but Burns said the clinical program will help them determine dosing frequency and duration of treatment.

"Our intent is by using these drops daily, people can eliminate entirely or at least reduce their dependency on readers," he said.

Recent News

Ashenafi 768x768
  • Our People
|Sep 20, 2023

Dr. Ashenafi Cherkos awarded prestigious AIM-AHEAD Fellowship in Leadership

Dr. Ashenafi Cherkos, assistant professor at The University of North Texas Health Science Center at Fort Worth, has been awarded the prestigious AIM-AHEAD Fellowship in Leadership for the Fall 2023 cohort. Cherkos serves in the School of Public Health’s Department of Population and Community Healt...
  • On Campus
|Sep 20, 2023

Innovate Fort Worth podcast: DJ Perera of New Age Media New Age Learning program

Innovate Fort Worth, the local podcast showcasing local innovation and its dynamic creators, recently featured DJ Perera, a trailblazing artist and educator. Hosted by Cameron Cushman of The University of North Texas Health Science Center at Fort Worth, the podcast episode delves into the intersecti...
Darlene Watkins
  • On Campus
|Sep 20, 2023

HSC student advocates for falls prevention awareness in Tarrant County

Darlene Watkins has dedicated her life to creating healthier and sustainable communities. Her background in interdisciplinary design led her to work with various community organizations from Atlanta to California, but it was her passion for educating aging populations that fueled her desire to wo...
Glenn Forister
  • On Campus
|Sep 19, 2023

HSC’s School of Health Professions to host Health Professions Workforce Symposium

Modern medicine is a team sport, and roughly 60% of that team is composed of practitioners who exist outside of the doctor-nurse paradigm. These vital pillars make up the backbone of the $3 trillion health care sector, and they’re among the fastest-growing professions in the world. From 5 to 8 p....